{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:37:39Z","timestamp":1791488259984,"version":"4.3.4"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Immunoglobulin A nephropathy (IgAN) remains the most common primary glomerulonephritis globally. Advances in mucosal immunology have illuminated the role of dysregulated B cell activity, galactose-deficient IgA1 (Gd-IgA1) and Gd-IgA1-specific antibody formation in driving disease pathogenesis. Therapeutic targeting of the mucosal immune system and, more specifically, B cell survival and differentiation pathways have entered late-stage development, offering a mechanistically guided approach to disease modification. Targeting of the gut-associated lymphoid tissue of the terminal ileum, B cell activating factor and\/or a proliferation-inducing ligand antagonists and CD38-targeted agents have all demonstrated efficacy in reducing proteinuria and preserving kidney function. Emerging cellular and bispecific platforms, although early in development, raise the prospect of deeper immunologic remodelling. Precision tools such as Gd-IgA1 quantification, single-cell transcriptomics and pharmacogenomics are being explored to optimise treatment selection and duration. As real-world data and long-term safety outcomes accumulate, B cell\u2013directed therapies are likely to become a commonly used treatment option in IgAN.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf322","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:54:48Z","timestamp":1763985288000},"page":"ii26-ii34","source":"Crossref","is-referenced-by-count":8,"title":["Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon"],"prefix":"10.1093","volume":"18","author":[{"given":"Lydia","family":"Roberts","sequence":"first","affiliation":[{"name":"University of Leicester Department of Cardiovascular Sciences, , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[{"name":"University of Leicester Department of Cardiovascular Sciences, , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2025121209163666600_bib1","first-page":"694","article-title":"Intercapillary deposits of IgA\u2013IgG","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol"},{"key":"2025121209163666600_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"2025121209163666600_bib3","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/ndt\/gfad082","article-title":"The incidence and prevalence of IgA nephropathy in Europe","volume":"38","author":"Willey","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163666600_bib4","volume-title":"IgA Nephropathy (Berger Disease)","author":"Rout","year":"2024"},{"key":"2025121209163666600_bib5","doi-asserted-by":"publisher","first-page":"1415026","DOI":"10.3389\/fimmu.2024.1415026","article-title":"Humoral immune responses primed by the alteration of gut microbiota were associated with galactose-deficient IgA1 production in IgA nephropathy","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"key":"2025121209163666600_bib6","doi-asserted-by":"crossref","first-page":"10340","DOI":"10.3390\/ijms251910340","article-title":"New insights and future perspectives of APRIL in IgA nephropathy","volume":"25","author":"Muto","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025121209163666600_bib7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.25259\/ijn_425_23","article-title":"IgA nephropathy: emerging mechanisms of disease","volume":"34","author":"Roberts","year":"2024","journal-title":"Indian J Nephrol"},{"key":"2025121209163666600_bib8","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163666600_bib9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.semnephrol.2007.10.009","article-title":"IgA glycosylation aberrancy in IgA nephropathy","volume":"28","author":"Novak","year":"2018","journal-title":"Semin Nephrol"},{"key":"2025121209163666600_bib10","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels","volume":"71","author":"Moldoveanu","year":"2007","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib11","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025121209163666600_bib12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163666600_bib13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3949\/ccjm.92a.24105","article-title":"IgA nephropathy: update on pathogenesis and treatment","volume":"92","author":"Ramsawak","year":"2025","journal-title":"Cleve Clin J Med"},{"key":"2025121209163666600_bib14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163666600_bib15","first-page":"iv31","article-title":"The pathogenesis of IgA nephropathy: recent insight from genetic studies","volume":"30","author":"Schaub","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163666600_bib16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.25259\/ijn_425_23","article-title":"IgA nephropathy: emerging mechanisms of disease","volume":"34","author":"Roberts","year":"2024","journal-title":"Indian J Nephrol"},{"key":"2025121209163666600_bib17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"2025121209163666600_bib18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2022","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"2025121209163666600_bib20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib21","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/ckj\/sfad274","article-title":"The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy","volume":"16","author":"Yeo","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025121209163666600_bib22","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"2025121209163666600_bib23","first-page":"1233","article-title":"A phase 2 trial of sibeprenlimab in IgA nephropathy","volume":"389","author":"Barratt","year":"2023","journal-title":"N Engl J Med"},{"key":"2025121209163666600_bib24","first-page":"2345","article-title":"BION-1301 in IgAN: phase 1\/2 interim results","volume":"8","author":"Lafayette","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025121209163666600_bib25","first-page":"629","article-title":"Atacicept in IgA nephropathy: results from the ORIGIN study","volume":"104","author":"Novartis","year":"2023","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163666600_bib27","first-page":"205","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Wang","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025121209163666600_bib28","article-title":"Alpine Immune Sciences shares updated clinical data from povetacicept in IgA nephropathy","author":"BusinessWire","year":"2024"},{"key":"2025121209163666600_bib29","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of povetacicept in adults with Immunoglobulin A nephropathy (RAINIER)","author":"Alpine Immune Sciences","year":"2025"},{"key":"2025121209163666600_bib30","article-title":"Long-term outcomes from the ENVISION phase 2 trial of sibeprenlimab in IgA nephropathy","author":"Jayne"},{"key":"2025121209163666600_bib31","first-page":"826","article-title":"Phase 2 trial of atacicept in IgA nephropathy: efficacy and safety from the ORIGIN study","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib32","first-page":"96","article-title":"Targeting CD38 in plasma cell dyscrasias: mechanisms and clinical implications","volume":"307","author":"Tai","year":"2022","journal-title":"Immunol Rev"},{"key":"2025121209163666600_bib33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib34","article-title":"A study of mezagitamab in adults with primary immunoglobulin A nephropathy receiving stable background therapy","author":"Takeda","year":"2025"},{"issue":"10S","key":"2025121209163666600_bib35","doi-asserted-by":"crossref","first-page":"ASN.20243d4074TQ","DOI":"10.1681\/ASN.20243d4074tq","article-title":"Safety, tolerability, and efficacy of mezagitamab (TAK-079) as add-on to standard of care therapy in individuals with primary IgA nephropathy: interim results from an open-label phase 1b study","volume":"35","author":"Barratt","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163666600_bib36","article-title":"Mezagitamab shows promise for IgA nephropathy in phase 1b trial, with Jonathan Barratt, MD, PhD","author":"Barratt","year":"2025","journal-title":"HCP Live"},{"key":"2025121209163666600_bib37","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib38","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163666600_bib39","doi-asserted-by":"crossref","first-page":"10340","DOI":"10.3390\/ijms251910340","article-title":"New insights and future perspectives of APRIL in IgA nephropathy","volume":"25","author":"Muto","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025121209163666600_bib40","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib41","first-page":"120","article-title":"Population pharmacodynamic modeling of inebilizumab in neuromyelitis optica spectrum disorder: evidence of rapid and sustained B cell depletion at 300\u202fmg intravenous dosing","volume":"434","author":"Yan","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2025121209163666600_bib42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","article-title":"Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial","volume":"23","author":"Cree","year":"2024","journal-title":"The Lancet Neurology"},{"key":"2025121209163666600_bib43","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.ekir.2023.09.024","article-title":"Randomized trial on the effect of an oral spleen tyrosine kinase inhibitor in the treatment of IgA nephropathy","volume":"8","author":"Tam","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025121209163666600_bib44","article-title":"Safety and efficacy study of fostamatinib to treat immunoglobulin A (IgA) nephropathy","author":"Rigel Pharmaceuticals"},{"key":"2025121209163666600_bib45","article-title":"Rigel announces topline data from proof-of-concept phase 2 study of fostamatinib in IgA nephropathy","year":"2018"},{"key":"2025121209163666600_bib46","first-page":"i489","article-title":"Spleen tyrosine kinase (SYK) inhibition with fostamatinib in IgA nephropathy: a global, phase II, randomised placebo-controlled trial of fostamatinib","volume":"34","author":"Tam","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163666600_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","article-title":"Comparative CNS pharmacology of Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis","volume":"24","author":"Turner","year":"2024","journal-title":"Drugs R D"},{"key":"2025121209163666600_bib48","doi-asserted-by":"crossref","first-page":"106138","DOI":"10.1016\/j.msard.2024.106138","article-title":"Fenebrutinib maintains low disease activity in relapsing MS: clinical and biomarker results from FENopta extension","volume":"92","author":"Bar-Or","year":"2024","journal-title":"Multiple Sclerosis Rel Dis"},{"key":"2025121209163666600_bib49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for reduction of proteinuria in IgA nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2025121209163666600_bib50","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for reduction of proteinuria in IgA nephropathy pilot trial","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2025121209163666600_bib51","first-page":"78","article-title":"Emerging immunotherapies in autoimmunity: lessons from hematologic malignancies","volume":"23","author":"Kansal","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2025121209163666600_bib52","first-page":"1326","article-title":"CAR-T cell therapy in refractory systemic lupus erythematosus","volume":"387","author":"Mackay","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121209163666600_bib53","first-page":"288","article-title":"Targeted B cell depletion and resetting in autoimmune disease: from theory to practice","volume":"19","author":"Ferraro","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025121209163666600_bib54","doi-asserted-by":"crossref","first-page":"e001157","DOI":"10.1136\/lupus-2024-001157","article-title":"CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?","volume":"12","author":"Kuipers","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2025121209163666600_bib55","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1111\/ajt.13393","article-title":"Intrarenal B cell cytokines promote transplant fibrosis and tubular atrophy","volume":"15","author":"Tse","journal-title":"Am J Transplant 2015"},{"key":"2025121209163666600_bib56","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaci.2019.07.004","article-title":"B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease","volume":"145","author":"Della-Torre","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025121209163666600_bib57","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/art.41798","article-title":"B cell depletion inhibits fibrosis via suppression of profibrotic macrophage differentiation in a mouse model of systemic sclerosis","volume":"73","author":"Numajiri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025121209163666600_bib58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/path.4831","article-title":"Renal recruitment of B lymphocytes exacerbates tubulointerstitial fibrosis by promoting monocyte mobilization and infiltration after unilateral ureteral obstruction","volume":"241","author":"Han","year":"2017","journal-title":"J Pathol"},{"key":"2025121209163666600_bib59","author":"Barratt","journal-title":"Phase 2 trial of sibeprenlimab in IgA nephropathy: proteinuria, immunoglobulins and safety"},{"key":"2025121209163666600_bib60","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of BION-1301 in adults with IgA nephropathy (The BEYOND Study)","author":"Novartis Pharmaceuticals"},{"key":"2025121209163666600_bib61","article-title":"A phase 2 study to evaluate the safety and efficacy of atacicept in multiple autoimmune glomerular diseases (PIONEER)","author":"Vera Therapeutics"},{"key":"2025121209163666600_bib62","first-page":"290","article-title":"Epidemiology and recurrence of IgA nephropathy in the transplant setting: challenges and opportunities with targeted biologics","volume":"43","author":"Schena","year":"2023","journal-title":"Semin Nephrol"},{"issue":"4S","key":"2025121209163666600_bib63","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib64","doi-asserted-by":"publisher","first-page":"1346769","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2024","journal-title":"Front Nephrol"},{"key":"2025121209163666600_bib65","doi-asserted-by":"publisher","first-page":"1461879","DOI":"10.3389\/fmed.2024.1461879","article-title":"Therapy of IgA nephropathy: time for a paradigm change","volume":"11","author":"Barratt","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2025121209163666600_bib66","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00467-017-3652-1","article-title":"The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition","volume":"33","author":"Coppo","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2025121209163666600_bib67","doi-asserted-by":"publisher","first-page":"8592","DOI":"10.3390\/ijms25168592","article-title":"Epigenetics, microbiome and personalized medicine: focus on kidney disease","volume":"25","author":"Gigliotti","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025121209163666600_bib68","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0140-6736(23)01952-9","article-title":"A new age of precision gene therapy","volume":"403","author":"Schambach","year":"2024","journal-title":"Lancet"},{"key":"2025121209163666600_bib69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"2025121209163666600_bib70","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: the lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"2025121209163666600_bib71","doi-asserted-by":"publisher","first-page":"e202350816","DOI":"10.1002\/eji.202350816","article-title":"Complement-targeted therapeutics: are we there yet, or just getting started?","volume":"54","author":"Ricklin","year":"2024","journal-title":"Eur J Immunol"},{"key":"2025121209163666600_bib72","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.ekir.2023.06.010","article-title":"Challenges in IgA nephropathy management: an era of complement inhibition","volume":"8","author":"Tesa\u0159","year":"2023","journal-title":"Kidney Int Rep"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf322\/65489528\/sfaf322.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_2\/ii26\/65489528\/sfaf322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_2\/ii26\/65489528\/sfaf322.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:16:50Z","timestamp":1765549010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/18\/Supplement_2\/ii26\/8341065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":72,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2025,12,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf322","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,24]]}}}